{"commentary":{"count":7,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":4,"x_thread":2,"youtube":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"CYCLONE 3","nct_id":"NCT05288166","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cyclone-3-nct05288166. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"CYCLONE 3","arms":[{"description":"Participants received 200 milligram (mg) abemaciclib twice daily (BID) in combination with standard doses of 1000 mg abiraterone acetate once daily and 5mg prednisone BID administered orally on a continuous dosing schedule on days 1 through 28 of a 28-day cycle until radiographic and/or symptomatic progression or until another discontinuation criterion is met.","label":"Abemaciclib","type":"EXPERIMENTAL"},{"description":"Participants received placebo BID in combination with standard doses of 1000 mg abiraterone acetate once daily and 5mg prednisone BID administered orally on a continuous dosing schedule on days 1 through 28 of a 28-day cycle until radiographic and/or symptomatic progression or until another discontinuation criterion is met.","label":"Placebo","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-10","type":"ESTIMATED"},"conditions":["Prostatic Neoplasms","Neoplasm Metastasis","Urogenital Neoplasms","Physiological Effects of Drugs","Antineoplastic Agents","Antineoplastic Agents, Hormonal","Androgens","Hormones","Hormones, Hormone Substitutes, and Hormone Antagonists","Abiraterone Acetate","Steroid Synthesis Inhibitors","Cytochrome P-450","Enzyme Inhibitors","Prednisone","Prednisolone","Cyclin-Dependent Kinase 4","Cyclin-Dependent Kinase 6"],"enrollment":{"count":925,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Abemaciclib","type":"DRUG"},{"name":"Abiraterone","type":"DRUG"},{"name":"Prednisone or Prednisolone","type":"DRUG"},{"name":"Placebo for Abemaciclib","type":"DRUG"}],"last_update":"2026-07-01","lead_sponsor":"Eli Lilly and Company","official_title":"CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-02-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Radiographic Progression-Free Survival (rPFS) Assessed by Investigator","timeFrame":"From Date of Randomization to Radiographic Disease Progression or Death from Any Cause (up to 22 months)"}],"references":[],"start_date":{"date":"2022-04-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)","url":"https://clinicaltrials.gov/study/NCT05288166"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cyclone-3-nct05288166"}